Pier Luigi Zinzani1, Armando Santoro2, Giuseppe Gritti3, Pauline Brice4, Paul M Barr5, John Kuruvilla6, David Cunningham7, Justin Kline8, Nathalie A Johnson9, Neha Mehta-Shah10, Thomas Manley11, Stephen Francis12, Manish Sharma12, Alison J Moskowitz13. 1. Institute of Hematology "Seràgnoli" Bologna University, Bologna, Italy. 2. IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy. 3. Ospedale Papa Giovanni XXIII, Bergamo, Italy. 4. Hôpital Saint-Louis, Paris, France. 5. University of Rochester, Rochester, NY. 6. Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 7. Royal Marsden Hospital, London, United Kingdom. 8. University of Chicago, Chicago, IL. 9. Jewish General Hospital, Montreal, Québec, Canada. 10. Washington University in St. Louis, St. Louis, MO. 11. Seattle Genetics, Bothell, WA. 12. Bristol-Myers Squibb, Princeton, NJ. 13. Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma with poor outcomes in patients with relapsed/refractory (R/R) disease. PMBL is characterized by high expression of programmed death-1 ligand and variable expression of CD30. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor, and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, may have synergistic activity in R/R PMBL. METHODS: The expansion cohort of the open-label, phase I/II CheckMate 436 study enrolled patients with confirmed R/R PMBL who were previously treated with either autologous hematopoietic cell transplantation or two or more prior chemotherapy regimens if ineligible for autologous hematopoietic cell transplantation. Patients received nivolumab (240 mg intravenously) and BV (1.8 mg/kg intravenously) every 3 weeks until disease progression or unacceptable toxicity. Primary end points were investigator-assessed objective response rate (ORR) per the Lugano 2014 criteria and safety. RESULTS: Thirty patients with PMBL were treated and evaluable. At a median follow-up of 11.1 months, ORR (95% CI) was 73% (54% to 88%), with a 37% complete remission rate per investigator, and ORR of 70% (51% to 85%), with a 43% complete metabolic response rate per independent review. Median duration of response, median progression-free survival, and median overall survival have not been reached. Eleven responders had consolidation with autologous (n = 5) or allogeneic (n = 6) transplantation. Treatment-related adverse events were reported in 25 patients (83%). Sixteen patients (53%) had grade 3 to 4 treatment-related adverse events; the most common were neutropenia (n = 9), thrombocytopenia (n = 3), and peripheral neuropathy (n = 3). There were no treatment-related deaths. CONCLUSION: In patients with R/R PMBL, the combination of nivolumab plus BV represents a promising option, with high antitumor activity and a manageable safety profile.
PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive non-Hodgkin lymphoma with poor outcomes in patients with relapsed/refractory (R/R) disease. PMBL is characterized by high expression of programmed death-1 ligand and variable expression of CD30. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor, and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, may have synergistic activity in R/R PMBL. METHODS: The expansion cohort of the open-label, phase I/II CheckMate 436 study enrolled patients with confirmed R/R PMBL who were previously treated with either autologous hematopoietic cell transplantation or two or more prior chemotherapy regimens if ineligible for autologous hematopoietic cell transplantation. Patients received nivolumab (240 mg intravenously) and BV (1.8 mg/kg intravenously) every 3 weeks until disease progression or unacceptable toxicity. Primary end points were investigator-assessed objective response rate (ORR) per the Lugano 2014 criteria and safety. RESULTS: Thirty patients with PMBL were treated and evaluable. At a median follow-up of 11.1 months, ORR (95% CI) was 73% (54% to 88%), with a 37% complete remission rate per investigator, and ORR of 70% (51% to 85%), with a 43% complete metabolic response rate per independent review. Median duration of response, median progression-free survival, and median overall survival have not been reached. Eleven responders had consolidation with autologous (n = 5) or allogeneic (n = 6) transplantation. Treatment-related adverse events were reported in 25 patients (83%). Sixteen patients (53%) had grade 3 to 4 treatment-related adverse events; the most common were neutropenia (n = 9), thrombocytopenia (n = 3), and peripheral neuropathy (n = 3). There were no treatment-related deaths. CONCLUSION: In patients with R/R PMBL, the combination of nivolumab plus BV represents a promising option, with high antitumor activity and a manageable safety profile.
Authors: Stephen M Ansell; Monique C Minnema; Peter Johnson; John M Timmerman; Philippe Armand; Margaret A Shipp; Scott J Rodig; Azra H Ligon; Margaretha G M Roemer; Nishitha Reddy; Jonathon B Cohen; Sarit Assouline; Michelle Poon; Manish Sharma; Kazunobu Kato; Selda Samakoglu; Anne Sumbul; Andrew Grigg Journal: J Clin Oncol Date: 2019-01-08 Impact factor: 44.544
Authors: Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp Journal: Blood Date: 2010-07-13 Impact factor: 22.113
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Georg Lenz; George W Wright; N C Tolga Emre; Holger Kohlhammer; Sandeep S Dave; R Eric Davis; Shannon Carty; Lloyd T Lam; A L Shaffer; Wenming Xiao; John Powell; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Lisa M Rimsza; Richard I Fisher; Dennis D Weisenburger; Wing C Chan; Louis M Staudt Journal: Proc Natl Acad Sci U S A Date: 2008-09-02 Impact factor: 11.205
Authors: David D W Twa; Fong Chun Chan; Susana Ben-Neriah; Bruce W Woolcock; Anja Mottok; King L Tan; Graham W Slack; Jay Gunawardana; Raymond S Lim; Andrew W McPherson; Robert Kridel; Adele Telenius; David W Scott; Kerry J Savage; Sohrab P Shah; Randy D Gascoyne; Christian Steidl Journal: Blood Date: 2014-02-04 Impact factor: 22.113
Authors: Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson Journal: N Engl J Med Date: 2013-04-11 Impact factor: 91.245
Authors: Ronald L Van Heertum; Robert Scarimbolo; John G Wolodzko; Barbara Klencke; Richard Messmann; Feza Tunc; Levi Sokol; Rajan Agarwal; James A Strafaci; Michael O'Neal Journal: Drug Des Devel Ther Date: 2017-06-13 Impact factor: 4.162
Authors: Jennifer L Crombie; Loretta J Nastoupil; Robert Redd; Kevin Tang; Geoffrey Shouse; Alex F Herrera; Victor A Chow; Mazyar Shadman; Omar Castaneda Puglianini; Anna Saucier; Caron A Jacobson; Philippe Armand; Gary Simmons Journal: Blood Adv Date: 2021-09-28